Key points from article :
Neuralink, Elon Musk’s brain-computer interface company, has reportedly raised $600 million, bringing its valuation to around $9 billion. Just last year, the company was valued at $3.5 billion after raising $280 million.
This sharp increase comes after some major milestones, including the successful implantation of Neuralink’s brain chip in three human patients as part of its PRIME clinical trial. These early tests showed the device’s ability to help people with severe disabilities regain some control over movement and communication. Neuralink has also announced its first clinical trial in the Middle East, to be held at Cleveland Clinic Abu Dhabi.
In addition, the company is preparing trials for a new device called Blindsight, designed to restore vision to blind individuals. It has received FDA Breakthrough Device Designation, which speeds up the approval process. Elon Musk has claimed this device may even help people blind from birth see for the first time. Despite still being far from commercial release, Neuralink has now surpassed many older and more established neurotechnology companies in valuation. With growing competition in the brain-tech space, this funding shows how much confidence investors place in both Neuralink’s progress and Musk’s leadership.
